Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
New insights into pleural mesothelioma
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
Liquid biopsy plays a growing role in early-stage lung cancer
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Further support for durvalumab consolidation as a new standard of care in limited-stage SCLC
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
Role of female leaders in addressing gender gaps in oncology
ESMO Women for Oncology Award Recipient Prof. Myung-Ju Ahn discusses gender equity in lung cancer research
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors